Development of a Methamphetamine Early Intervention
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01174654 |
Recruitment Status
:
Completed
First Posted
: August 3, 2010
Last Update Posted
: December 13, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Sexual Behavior Methamphetamine Behavioral Research | Behavioral: Contingency management | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 127 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Prevention |
Official Title: | Development of a Methamphetamine Early Intervention |
Study Start Date : | December 2006 |
Actual Primary Completion Date : | April 2009 |
Actual Study Completion Date : | April 2009 |

Arm | Intervention/treatment |
---|---|
No Intervention: Referral to community resources | |
Experimental: Contingency Management |
Behavioral: Contingency management
A 12-week contingency management intervention
Other Name: Voucher-based reinforcement
|
- Non-concordant unprotected anal intercourse [ Time Frame: Baseline, 6, 12, 18, 24 weeks ]
- Number of non-concordant unprotected anal intercourse partners [ Time Frame: Baseline, 6, 12, 18, 24 weeks ]
- Stimulant (methamphetamine and crack/cocaine) urinalyses [ Time Frame: Baseline, 6, 12, 18, 24 weeks ]
- Self-reported methamphetamine use [ Time Frame: Baseline, 6, 12, 18, 24 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Anal sex with another man in the month prior to enrollment
- Use of methamphetamine on at least 2 days in the month prior to enrollment
Exclusion Criteria:
- Plans to move from the study catchment area within 6 months of enrollment
- A mutually monogamous relationships with a man of the same HIV status lasting 2 or more years

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01174654
United States, Washington | |
Lifelong AIDS Alliance | |
Seattle, Washington, United States, 98122 |
Principal Investigator: | Matthew Golden | University of Washington |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | University of Washington |
ClinicalTrials.gov Identifier: | NCT01174654 History of Changes |
Other Study ID Numbers: |
R21DA019420-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | August 3, 2010 Key Record Dates |
Last Update Posted: | December 13, 2012 |
Last Verified: | December 2012 |
Additional relevant MeSH terms:
Methamphetamine Central Nervous System Stimulants Physiological Effects of Drugs Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Dopamine Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Dopamine Uptake Inhibitors |